lifestyle.marketresearchjournals.com

Author: Actuate Therapeutics

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

May 7, 2026
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

April 15, 2026
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

March 9, 2026
Actuate Therapeutics to Present at The Citizens Life Sciences Conference

March 5, 2026
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 24, 2026
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

January 27, 2026